MA68586A1 - Acide nucléique à codons optimisés codant pour fviii-bdd - Google Patents

Acide nucléique à codons optimisés codant pour fviii-bdd

Info

Publication number
MA68586A1
MA68586A1 MA68586A MA68586A MA68586A1 MA 68586 A1 MA68586 A1 MA 68586A1 MA 68586 A MA68586 A MA 68586A MA 68586 A MA68586 A MA 68586A MA 68586 A1 MA68586 A1 MA 68586A1
Authority
MA
Morocco
Prior art keywords
bdd
codon
nucleic acid
optimized nucleic
acid encoding
Prior art date
Application number
MA68586A
Other languages
English (en)
Inventor
Pavel Andreevich IAKOVLEV
Dmitry Valentinovich MOROZOV
Anna Nikolaevna STRELKOVA
Mariya Pavlovna PEREPELKINA
Pavel Mikhailovich GERSHOVICH
Tatiana Evgenievna SHUGAEVA
Elena Veniaminovna VLASOVA
Anastasiia Vladimirovna FOMINA
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022111734A external-priority patent/RU2808564C2/ru
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA68586A1 publication Critical patent/MA68586A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention relève des domaines de la génétique, de la thérapie génique et de la biologie moléculaire. Plus particulièrement, la présente invention concerne un acide nucléique à codons optimisés qui code pour la protéine FVIII-BDD (facteur VIII de coagulation à domaine B supprimé), une cassette d'expression et un vecteur basé sur celui-ci, une cellule hôte pour produire FVIII-BDD, ainsi que diverses utilisations du vecteur ci-dessus.
MA68586A 2022-04-28 2023-04-18 Acide nucléique à codons optimisés codant pour fviii-bdd MA68586A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2022111734A RU2808564C2 (ru) 2022-04-28 Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение
PCT/RU2023/050094 WO2023211316A1 (fr) 2022-04-28 2023-04-18 Acide nucléique à codons optimisés codant pour fviii-bdd

Publications (1)

Publication Number Publication Date
MA68586A1 true MA68586A1 (fr) 2025-04-30

Family

ID=88482201

Family Applications (1)

Application Number Title Priority Date Filing Date
MA68586A MA68586A1 (fr) 2022-04-28 2023-04-18 Acide nucléique à codons optimisés codant pour fviii-bdd

Country Status (20)

Country Link
US (1) US20250282847A1 (fr)
EP (1) EP4514836A1 (fr)
JP (1) JP2025514313A (fr)
KR (1) KR20250007615A (fr)
CN (1) CN116970629A (fr)
AR (1) AR129163A1 (fr)
AU (1) AU2023261338A1 (fr)
CA (1) CA3250665A1 (fr)
CL (1) CL2024003296A1 (fr)
CO (1) CO2024014690A2 (fr)
CR (1) CR20240524A (fr)
IL (1) IL316584A (fr)
JO (1) JOP20240241A1 (fr)
MA (1) MA68586A1 (fr)
MX (1) MX2024013280A (fr)
PE (1) PE20251838A1 (fr)
PY (1) PY2331315A (fr)
TW (1) TW202346601A (fr)
UY (1) UY40241A (fr)
WO (1) WO2023211316A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075619A1 (fr) * 2015-10-30 2017-05-04 Spark Therapeutics, Inc. Variants du facteur viii à cpg réduit, compositions, procédés et utilisations pour le traitement d'affections hémostatiques
WO2017083762A1 (fr) * 2015-11-13 2017-05-18 Baxalta Incorporated Vecteurs viraux codant pour des variants fviii de recombinaison avec une expression accrue pour la thérapie génique de l'hémophilie a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003399A2 (pt) * 2018-08-24 2021-05-18 Spark Therapeutics, Inc. sequências de promotores otimizadas, construtos de expressão livres de íntron e métodos de uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075619A1 (fr) * 2015-10-30 2017-05-04 Spark Therapeutics, Inc. Variants du facteur viii à cpg réduit, compositions, procédés et utilisations pour le traitement d'affections hémostatiques
WO2017083762A1 (fr) * 2015-11-13 2017-05-18 Baxalta Incorporated Vecteurs viraux codant pour des variants fviii de recombinaison avec une expression accrue pour la thérapie génique de l'hémophilie a

Also Published As

Publication number Publication date
CR20240524A (es) 2025-05-05
JP2025514313A (ja) 2025-05-02
CN116970629A (zh) 2023-10-31
PY2331315A (es) 2023-10-31
AU2023261338A1 (en) 2024-11-21
AR129163A1 (es) 2024-07-24
UY40241A (es) 2023-10-13
CL2024003296A1 (es) 2025-02-21
WO2023211316A1 (fr) 2023-11-02
JOP20240241A1 (ar) 2024-10-27
CA3250665A1 (fr) 2023-11-02
IL316584A (en) 2024-12-01
PE20251838A1 (es) 2025-07-17
MX2024013280A (es) 2024-12-06
KR20250007615A (ko) 2025-01-14
TW202346601A (zh) 2023-12-01
US20250282847A1 (en) 2025-09-11
CO2024014690A2 (es) 2025-03-06
EP4514836A1 (fr) 2025-03-05

Similar Documents

Publication Publication Date Title
Iriarte et al. Codon usage bias: an endless tale
Muller et al. In the human malaria parasite Plasmodium falciparum, polyamines are synthesized by a bifunctional ornithine decarboxylase, S-adenosylmethionine decarboxylase
Thorpe et al. Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities
MA62178A1 (fr) Effet synergique de smn1 et mir-23a dans le traitement de l'amyotrophie spinale
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
Sukhodolets et al. RapA, a novel RNA polymerase-associated protein, is a bacterial homolog of SWI2/SNF2
MA58655B1 (fr) Acide nucléique optimisé par codons qui code la protéine smn1
DE69943286D1 (de) Fluoreszierende proteine aus nicht-biolumineszenten arten der klasse anthozoa, gene die diese proteine kodieren und deren verwendungen
Dudkina et al. New insight into secreted ribonuclease structure: binase is a natural dimer
MX2023001888A (es) Variantes de una xiloglucanasa de la familia 44.
BR0115722A (pt) Genes de desenvolvimento floral
Kim et al. Sequence divergence of seryl-tRNA synthetases in archaea
MA68586A1 (fr) Acide nucléique à codons optimisés codant pour fviii-bdd
Halder et al. Nucleotide composition determines the role of translational efficiency in human genes
CY1105650T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-21
MA68435A1 (fr) Acide nucléique isolé codant pour une protéine de fusion à base de fviii-bdd et d'un peptide de signal hétérologue
FR2823764B1 (fr) Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
AR026983A1 (es) Genes de moho y algas que codifican proteinas que intervienen en la sintesis de tocoferoles y carotenoides
Gorbunov et al. Biosynthesis and secretion of serine peptidase SerP38 from Tenebrio molitor in the yeast Komagataella kurtzmanii
DK0668917T3 (da) Riboflavinsyntese i gær
Szabó et al. Tyrosine sulfation of human trypsin steers S2’subsite selectivity towards basic amino acids
Demidyuk et al. Modification of substrate-binding site of glutamyl endopeptidase from Bacillus intermedius
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
ATE266731T1 (de) Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung
Ennes-Vidal et al. Expression and cellular localisation of Trypanosoma cruzi calpains